Antibiotic resistance

Medical Clinics of North America

Volumn 84, Issue 6, 2000, Pages 1407-1429

  Cunha, Burke A ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; METICILLIN; MINOCYCLINE; NITROFURANTOIN; PENICILLIN G; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL MUTATION; BACTERIUM CULTURE; CROSS RESISTANCE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULARY; DRUG SENSITIVITY; DRUG TISSUE LEVEL; DRUG USE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033647252     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70295-9     Document Type: Article

References (186)

1. Broad- and narrow-spectrum antibiotics: An unhelpful categorization
2. Consequences of bacterial resistance to antibiotics in medical practice
3. Trends in bacterial resistance to fluoroquinolones
4. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determinations
5. Antimicrobial resistance in Streptococcus pneumoniae: An overview
6. Role of the newer fluoroquinolones against penicillin-resistant Streptococcus pneumoniae
7. In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak
8. United States Geographic Bacteria Susceptibility Patterns
9. Bacterial resistance to antimicrobial agents: Selected problems in France, 1996-1998
10. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America
11. From micrococcus to Moraxella: The reemergence of Branhamella catarrhalis
12. Antimicrobial usage and resistance problems: Surveillance issues and a strategy for the future
13. Impact of prior antibiotic therapy for acute otitis media on pathogen susceptibility in a subsequent episode
14. Pseudomonas aeruginosa: A survey of resistance in 136 hospitals in Spain
15. Emergence of drug resistant pneumococcal infections in the United States
16. Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis
17. Molecular epidemiologic analysis of multiresistant Klebsiella pneumoniae isolates from a pediatric hospital
18. The role of newer macrolides in the treatment of community-acquired respiratory tract infection: A review of experimental and clinical data
19. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents
20. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa
21. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States 1997
22. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
23. One dose ceftriaxone vs. ten days of amoxicillin/clavulanate therapy for acute otitis media: Clinical efficacy and change in nasopharyngeal flora
24. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected from five centers in Brazil, 1997-98
25. Newer macrolide antibiotics: Advantages and uses
26. Problems arising in antimicrobial therapy due to false susceptibility testing
27. Antibiotic resistance: Control strategies
28. Factors in antibiotic selection for hospital formularies (Part I and II)
29. Prevention of aminoglycoside resistance by the use of amikacin
30. Penicillin-resistant pneumococci
31. Antibiotic resistance: Myths, truths, and a rational formulary approach
32. Doxycycline re-revisited
33. Penicillin resistant Streptococcus pneumoniae infections
34. Ciprofloxacin resistant S. pneumoniae not fluoroquinolone resistant S. pneumoniae
35. Antibiotic resistance: A historical perspective
36. Emerging resistant organisms in the outpatient setting
37. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae
38. An antibiotic policy to prevent emergence of resistant bacilli
39. Strategies for selecting antibiotics in intensive care units
40. Vancomycin-resistant Enterococcus faecium in a Veterans Affairs Medical Center: Association with antibiotic usage
41. Survey of bloodstream infections due to gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY antimicrobial surveillance program, 1997
42. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract
43. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study
44. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
45. Effects of antibiotic therapy on Pseudomonas aeruginosa induced lung injury in a rat model
46. Amoxicillin and AOM: Should we increase the dose
47. Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin
48. Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of staphylococcal abscess
49. Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance
50. Development of resistance during antimicrobial therapy: A review of antibiotic classes and patient characteristics in 173 studies
51. Antimicrobial resistance among Haemophilus influenzae isolates
52. Enterococci and vancomycin resistance
53. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals
54. Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes
55. Prevalence of vancomycin-resistant enterococci in fecal samples from hospitalized patients and nonhospitalized controls in a cattle-rearing area of France
56. Influence of comorbidity and severity on the clinical outcome of bacteremic pneumococcal pneumonia treated with β-lactam monotherapy
57. Emergence and dissemination of quinolone-resistant Escherichia coli in the community
58. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides
59. Population-based assessment of the mechanisms of high-level erythromycin resistance in Streptococcus pneumoniae
60. Emerging nosocomial infections and antimicrobial resistance
61. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia
62. Comparative in vitro activities of amoxicillin-clavulanate against aerobic and anaerobic bacteria isolated from antral puncture specimens from patients with sinusitis
63. Quinolone resistance in veterinary isolates of Salmonella
64. Practical strategies for the appropriate use of antimicrobials
65. Antibiotic use and pneumococcal resistance to penicillin: The French experience
66. Low dosage and long treatment duration of beta-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae
67. Growth in the presence of salicylate increases fluoroquinolone resistance in Staphylococcus aureus
68. Diminished activity of ceftizoxime in comparison to cefotaxime and ceftriaxone against Streptococcus pneumoniae
69. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa
70. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
71. Macrolide susceptibility and β-lactamase production among Haemophilus influenzae isolates in the United States, 1996-1997
72. Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan
73. In vitro comparative activity of meropenem with 15 other antimicrobial agents against 1798 Pseudomonas aeruginosa isolates in a French multicenter study
74. Drug-resistant Streptococcus pneumoniae: Rational antibiotic choices
75. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae
76. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study
77. Antimicrobial-resistant pathogens in the 1990s
78. Prevalence and resistance mechanisms of common bacterial respiratory pathogens
79. Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: The complexity of the problem
80. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP)
81. Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents
82. Prevalence and characterization of the mechanisms of macrolide, lincosamide and streptogramin resistance in isolates of Streptococcus pneumoniae
83. Transfer of erythromycin resistance from poultry to human clinical strains of Staphylococcus aureus
84. Management of infections due to antibiotic-resistant Streptococcus pneumoniae
85. Modification of prescribers' behavior: The Icelandic approach
86. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
87. Reduction in the incidence of methicillin-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary
88. Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: Risk factors and outcome
89. Low-level colonization and infection with ciprofloxacin-resistant gram-negative bacilli in a skilled nursing facility
90. Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance
91. Changes in intestinal flora of farm personnel after introduction of tetracycline-supplemented feed on a farm
92. Fluoroquinolone resistance in Streptococcus pneumoniae
93. Antimicrobial resistance of Streptococcus pneumoniae: Comparison of the in vitro activity of 16 antibiotics
94. Pharmacodynamics of trovafloxacin, ofloxacin and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model
95. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: Comparison of clinical features and outcomes
96. Hospital study of adult community-acquired pneumonia
97. Doxycycline in respiratory infections: A reassessment after 17 years
98. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine
99. Animal feed antibiotic use raises drug resistance fear
100. Antimicrobial resistance in hospital organisms and its relation to antibiotic use
101. Aminoglycosides: Activity and resistance
102. Oropharyngeal gram-negative bacillary carriage
103. A harbinger of microbial resistance to antibiotics
104. Imipenem resistance in aerobic gram-negative bacteria
105. Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam
106. Vancomycin-resistant enterococci
107. Introduction: Problems with antimicrobial resistance in gram-positive cocci
108. Infections caused by erythromycin-resistant Streptococcus pneumoniae: Incidence, risk factors, and response to therapy in a prospective study
109. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo
110. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs Medical Center
111. Intensive care antimicrobial resistance epidemiology (ICARE) surveillance report, data summary from January 1996 through December 1997
112. Infections and antibiotic resistance in nursing homes
113. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis
114. Negative regulation of the Pseudomonas aeruginosa outer membrane porin oprD selective for imipenem and basic amino acids
115. Bactericidal effects of levofloxacin in comparison with those of ciprofloxacin and sparfloxacin
116. Vancomycin-resistant enterococci in intensive care units
117. Decrease of vancomycin-resistant enterococci in poultry meat after avoparcin ban
118. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia
119. Patterns and modes of β-lactam resistance in Pseudomonas aeruginosa
120. Fluoroquinolone resistance in Streptococcus pneumoniae
121. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
122. Quinolone resistance and Campylobacter
123. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
124. Spread of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: Are β-lactamase inhibitors of therapeutic value?
125. Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics
126. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli
127. Bacteremia with Streptococcus pneumoniae: Implications for therapy and prevention
128. Effect of changes in antimicrobial agent use on bacterial pathogens recovered from hospitalized patients: A 6-year assessment
129. Manipulation of a hospital formulary to control an outbreak of vancomycin-resistant enterococci
130. Clinical relevance of penicillin-resistant Streptococcus pneumoniae with particular attention to therapy with ceftizoxime, cefotaxime, and ceftriaxone
131. Clinical role of fluoroquinolones in patients with respiratory tract infections
132. Antimicrobial resistance in anaerobes
133. Tn916 family conjugative transposons and dissemination of antimicrobial resistance determinants
134. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center
135. Fluoroquinolone use and fluoroquinolone resistance: Is there an association?
136. Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia
137. Treatment of severe infections caused by penicillin-resistant pneumococci: Role of third generation cephalosporins
138. Susceptibility of penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobial agents
139. Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period
140. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia
141. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen
142. Genesis of methicillin-resistant Staphylococcus aureus (MRSA): How treatment of MRSA infections was selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control
143. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation
144. A randomized comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults
145. Resistant pneumococcus: A worldwide problem
146. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: Case report and review
147. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland
148. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland
149. Doxycycline activity against Streptococcus pneumoniae
150. Prevalence of macrolide mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995
151. Novel mechanism of macrolide resistance in Streptococcus pneumoniae
152. The significance of serum vs. tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia: Are we looking in the wrong place?
153. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998
154. Antibiotic resistance: The Bermuda experience
155. Post-antibiotic effect and post-antibiotic sub-MIC effects of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci
156. Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 β-lactamase production and loss of an outer membrane protein
157. Antibiotic resistance: Strategies for counterattack
158. The safety profile of fluoroquinolones
159. Antibiotic policy: A tool for controlling resistance of hospital pathogens
160. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae
161. Detection of carbapenemase-producing Acinetobacter baumanii in a hospital
162. In vitro activities of oral β-lactams at concentrations achieved in humans against penicillin-susceptible and -resistant pneumococci and potential to select resistance
163. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
164. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S. study
165. Resistance to ciprofloxacin in pathogenic Enterobacteriaceae in England and Wales in 1996
166. Resistance to ciprofloxacin in non-typhoidal salmonellas from humans in England and Wales - The current situation
167. Ciprofloxacin-resistant Salmonella typhi and treatment failure
168. New faces of an old pathogen: Emergence and spread of multidrug-resistant Streptococcus pneumoniae
169. Epidemiological analysis of imipenem-resistant Serratia marcescens in hospitalized patients
170. Rare case of failure by an automated system to detect extended-spectrum β-lactamase in a cephalosporin-resistant Klebsiella pneumoniae isolate
171. Bacterial resistance to ciprofloxacin in Greece: Results from the national electronic surveillance system
172. Clinical aspects of antimicrobial resistance
173. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill
174. Bactericidal activities of ceftizoxime and cefotaxime against Streptococcus pneumoniae
175. Hemophilus influenzae pneumonia in adults
176. An international perspective on antimicrobial resistance
177. Editorial response: Managing antibiotic use-impact of infection control
178. Vancomycin-resistant Staphylococcus aureus: Infection control considerations
179. Mechanisms of quinolone resistance
180. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes
181. Outer membrane protein profiles of Xanthomonas maltophilia isolates displaying temperature-dependent susceptibility to gentamicin
182. Predicting susceptibility of Streptococcus pneumoniae to ceftriaxone and cefotaxime by cefuroxime and ceftizoxime disk diffusion testing
183. Penicillin-nonsusceptible Streptococcus pneumoniae at San Francisco General Hospital
184. Multi-center study of the in vitro activity of cefepime in comparison with five other broad-spectrum antibiotics against clinical isolates of gram-positive and gram-negative bacteria from hospitalized patients in Switzerland
185. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: Results of a Canadian national surveillance study